Shares of Penumbra (NYSE:PEN) hit a new 52-week high and low during trading on Friday . The stock traded as low as $159.35 and last traded at $158.80, with a volume of 3628 shares traded. The stock had previously closed at $155.95.
Several analysts recently commented on PEN shares. Goldman Sachs started coverage on Penumbra in a research report on Wednesday, April 4th. They set a “buy” rating and a $145.00 price target for the company. William Blair started coverage on Penumbra in a research report on Wednesday, February 21st. They set an “outperform” rating for the company. Canaccord Genuity reiterated a “buy” rating and set a $113.00 price target on shares of Penumbra in a research report on Wednesday, January 24th. Wells Fargo boosted their price target on Penumbra to $138.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 13th. Finally, BMO Capital Markets boosted their price target on Penumbra from $110.00 to $115.00 and gave the stock a “market perform” rating in a research report on Wednesday, February 28th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $152.60.
The stock has a market capitalization of $5.32 billion, a P/E ratio of -15,825.00, a P/E/G ratio of 47.08 and a beta of -0.01.
Penumbra (NYSE:PEN) last issued its quarterly earnings results on Tuesday, May 8th. The company reported $0.06 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.02) by $0.08. Penumbra had a return on equity of 1.13% and a net margin of 3.65%. The firm had revenue of $102.70 million during the quarter, compared to analysts’ expectations of $90.98 million. During the same period in the previous year, the business earned ($0.10) earnings per share. The firm’s revenue for the quarter was up 40.3% on a year-over-year basis. analysts anticipate that Penumbra will post 0.17 earnings per share for the current fiscal year.
In other Penumbra news, EVP Robert D. Evans sold 10,000 shares of the company’s stock in a transaction on Monday, March 12th. The stock was sold at an average price of $121.03, for a total value of $1,210,300.00. Following the completion of the sale, the executive vice president now directly owns 12,225 shares in the company, valued at approximately $1,479,591.75. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Lynn Rothman sold 2,273 shares of the company’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $115.00, for a total value of $261,395.00. Following the completion of the sale, the executive vice president now owns 154,046 shares of the company’s stock, valued at $17,715,290. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 43,900 shares of company stock valued at $5,653,183. 10.70% of the stock is owned by company insiders.
Large investors have recently modified their holdings of the business. Advisors Preferred LLC purchased a new stake in Penumbra in the 1st quarter valued at $101,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Penumbra by 45.9% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,691 shares of the company’s stock valued at $159,000 after buying an additional 532 shares in the last quarter. Public Employees Retirement Association of Colorado purchased a new stake in Penumbra in the 4th quarter valued at $189,000. Aperio Group LLC purchased a new stake in Penumbra in the 4th quarter valued at $236,000. Finally, Xact Kapitalforvaltning AB purchased a new stake in Penumbra in the 4th quarter valued at $269,000. Institutional investors own 73.21% of the company’s stock.
Penumbra Company Profile
Penumbra, Inc designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands; aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the ACE and the 3D Revascularization Device brands.
Receive News & Ratings for Penumbra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Penumbra and related companies with MarketBeat.com's FREE daily email newsletter.